0001062993-18-003711.txt : 20180911
0001062993-18-003711.hdr.sgml : 20180911
20180911212338
ACCESSION NUMBER: 0001062993-18-003711
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180910
FILED AS OF DATE: 20180911
DATE AS OF CHANGE: 20180911
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wegman Mark N
CENTRAL INDEX KEY: 0001405235
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34236
FILM NUMBER: 181065856
MAIL ADDRESS:
STREET 1: 43 OVERLOOK ROAD
CITY: OSSINING
STATE: NY
ZIP: 10562
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP
CENTRAL INDEX KEY: 0000875622
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 113054851
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 WILBUR ST
CITY: LYNBROOK
STATE: NY
ZIP: 11563
BUSINESS PHONE: 5165937000
MAIL ADDRESS:
STREET 1: 35 WILBUR STREET
CITY: LYNBROOK
STATE: NY
ZIP: 11563
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2018-09-10
0000875622
BIOSPECIFICS TECHNOLOGIES CORP
BSTC
0001405235
Wegman Mark N
C/O BIOSPECIFICS TECHNOLOGIES CORP.
35 WILBUR STREET
LYNBROOK
NY
11563
1
0
0
0
Common Stock, $0.001 par value
2018-09-10
4
S
0
5500
57.3102
D
66272
D
Common Stock, $0.001 par value
2018-09-11
4
S
0
1000
58.655
D
65272
D
The selling price of $57.3102 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $56.22 to $58.902. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The selling price of $58.655 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $58.64 to $58.67. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
/s/ Mark Wegman by Carl A. Valenstein, attorney- in-fact
2018-09-11